SCHEMBL6503003

SCHEMBL6503003

COc1cccc(-c2ccc(C(=O)NC3CC4CNC3C4)o2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 1/20 0.47
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
KMT2A Q03164 4/20 0.43
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
ABCB1 P08183 1/20 0.43
MEN1 O00255 3/20 0.42
C3AR1 Q16581 1/20 0.42
MAPT P10636 3/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6496636 0.89 SLC9A1 (0.45) SLC9A1NPC1RAB9AKMT2AALDH1A1
SCHEMBL6500577 0.89 MAPKAPK2 (0.45) NPC1RAB9AKMT2AALDH1A1SMN1; SMN2
SCHEMBL6498910 0.88 NPC1 (0.43) NPC1RAB9AALDH1A1SMN1; SMN2HPGD
SCHEMBL6496663 0.87 NPC1 (0.42) SLC9A1NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL6496911 0.87 NR4A1 (0.50) SLC9A1NPC1RAB9AKMT2AALDH1A1
SCHEMBL6487729 0.87 ALDH1A1 (0.57) SLC9A1NPC1RAB9AKMT2AALDH1A1
SCHEMBL6488167 0.86 S1PR4 (0.43) NPC1RAB9AKMT2AALDH1A1SMN1; SMN2
SCHEMBL6486481 0.85 HDAC1 (0.51) NPC1RAB9AKMT2AALDH1A1SMN1; SMN2
SCHEMBL6487288 0.85 NQO2 (0.50) NPC1RAB9AKMT2AALDH1A1SMN1; SMN2
SCHEMBL6486913 0.82 SLC9A1 (0.48) SLC9A1NPC1RAB9AKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
EP-1442041-A1 AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-08-04 EP disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed
WO-2003040147-A1 AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE__________________________________________________________________________________________________________________________ PHARMACIA & UPJOHN COMPANY (US) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 SLC9A1 1193/4885NPC1 224/4885RAB9A 1437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.